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Abstract
Imerslund-Gra¨sbeck syndrome (IGS) or selective cobalamin malabsorption has been described in humans and dogs. IGS
occurs in Border Collies and is inherited as a monogenic autosomal recessive trait in this breed. Using 7 IGS cases and 7 non-
affected controls we mapped the causative mutation by genome-wide association and homozygosity mapping to a 3.53 Mb
interval on chromosome 2. We re-sequenced the genome of one affected dog at ,106 coverage and detected 17 non-
synonymous variants in the critical interval. Two of these non-synonymous variants were in the cubilin gene (CUBN), which
is known to play an essential role in cobalamin uptake from the ileum. We tested these two CUBN variants for association
with IGS in larger cohorts of dogs and found that only one of them was perfectly associated with the phenotype. This
variant, a single base pair deletion (c.8392delC), is predicted to cause a frameshift and premature stop codon in the CUBN
gene. The resulting mutant open reading frame is 821 codons shorter than the wildtype open reading frame (p.Q2798Rfs*3).
Interestingly, we observed an additional nonsense mutation in the MRC1 gene encoding the mannose receptor, C type 1,
which was in perfect linkage disequilibrium with the CUBN frameshift mutation. Based on our genetic data and the known
role of CUBN for cobalamin uptake we conclude that the identified CUBN frameshift mutation is most likely causative for IGS
in Border Collies.
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Introduction
Cobalamin is a member of the B-group, water soluble vitamins.
Cobalamin is also known as vitamin B12. The abbreviation B12
covers all forms of cobalamins (i.e. all compounds with a corrin
ring structure) and not only cyanocobalamin, which is the vitamin
B12 [1]. Higher organisms such as plants or animals are unable to
synthesize cobalamin. Mammals rely on either dietary cobalamin
or symbiontic microorganisms to obtain this essential compound.
Vitamin B12 serves as coenzyme for 5-methyltetrahydrofolate-
homocysteine methyltransferase (MTR) and methylmalonyl co-
enzyme A mutase (MUT). Deficiency of cobalamin leads to
reduced activity of both of these enzymes resulting in an increase
of methylmalonic acid (MMA) and total homocysteine (tHcy).
Therefore, measurements of these metabolites allow the assess-
ment of cellular cobalamin availability and are the tests of choice
to detect early or mild cobalamin deficiency in humans [1].
MTR is involved in the synthesis of DNA. Therefore, a lack of
cobalamin affects rapidly dividing cells and leads to changes in the
hematopoietic system such as megaloblastic anemia. Chronic
deficiency of cobalamin also leads to neurological symptoms and
irreversible damage of the brain and nervous system [1].
The uptake of dietary cobalamin in mammals is a complex
process requiring several endogenous proteins. In the small
intestine the dietary cobalamin (‘‘extrinsic factor’’) is bound to
a secreted protein, called gastric intrinsic factor (GIF). The uptake
of the cobalamin-GIF complex from the intestinal lumen into the
body is mediated by a specific membrane protein complex termed
cubam receptor [2,3]. Cubam consists of two separate protein
subunits, amnionless (AMN) and cubilin (CUBN).
Mutations in either the AMN or CUBN genes lead to Imerslund-
Gra¨sbeck syndrome (IGS) or selective cobalamin malabsorption
[4,5]. IGS in humans is a rare autosomal recessive disorder, which
results in megaloblastic anemia, mild proteinuria, failure to thrive,
and neurological damage when untreated. IGS can be successfully
managed by supplementation with regular doses of cobalamin [6].
Primary cobalamin absorption disorders have also been
reported in several dog breeds including Australian Shepherd
Dogs [7], Beagles [8], Border Collies [9–12], Giant Schnauzers
[13], and Shar-Peis [14]. Two independent mutations in the AMN
gene cause IGS in Australian Shepherd Dogs and Giant
Schnauzers, respectively [7]. The molecular defect in the other
dog breeds has not yet been reported.
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We previously described clinical and laboratory findings in
young Border Collies with IGS and established breed-specific
reference parameters for serum cobalamin, urine methymalonic
acid, and plasma homocysteine concentrations in Border Collies
[12,15]. The goal of the present study was the identification of
the causative mutation for IGS in the Border Collie breed.
Results
Phenotypic Description
We previously described the clinical phenotype of IGS in
Border Collies in detail [12]. Briefly, affected dogs were young
(median 11.5 months, range 8–42 months) when finally
diagnosed. Historical complaints included intermittent diarrhea,
inappetence (picky appetite to anorexia) with poor body
condition (BCS 2–3/9), and failure to grow. Clinically the
marked weakness and small growth were the predominant
findings. Additional clinical signs included odynophagia, glossi-
tis, and bradyarrhythmia. Pertinent laboratory abnormalities
consisted of mild to moderate normocytic, non-regenerative
anemia with evidence of dyserythropoesis (increased numbers of
nucleated red blood cells), increased aspartate-aminotransferase
activity, and mild proteinuria. All dogs had serum cobalamin
levels below the detection limit of the assay, as well as marked
methylmalonic aciduria and hyperhomocysteinemia. We
achieved full clinical recovery in all dogs with regular parenteral
cobalamin supplementation [12].
Mapping of the Causative Mutation
We genotyped 173,662 evenly spaced SNPs on DNA samples
from 7 affected Border Collies and 7 controls. After removing
61,339 markers, which had bad call rates (,90%), were non-
informative (MAF ,0.05), or showed a strong deviation from
Hardy-Weinberg equilibrium in the controls (p,1025), we
retained 112,323 markers for the final genome-wide allelic
association study. Three best-associated SNPs in the GWAS had
identical raw p-values of 4.661026 (Figure 1A). The corrected p-
value after 100,000 permutations was 0.046. The 19 best-
associated SNPs with raw p-values of less than 861025 were all
located on CFA 2 (Figure 1B). It has to be cautioned that the
genomic inflation factor in this analysis was 1.36. This high value
indicates sample stratification, which was caused by the use of
closely related dogs including one full-sib pair among the cases. As
the GWAS results showed an unequivocal signal we did not
perform sophisticated corrections for the stratification in our
samples.
Subsequently, we applied a homozygosity mapping approach to
fine-map the region containing the disproportionate dwarfism
mutation. We hypothesized that the affected dogs most likely were
inbred to one single founder animal. Under this scenario the
affected individuals were expected to be identical by descent (IBD)
for the causative mutation and flanking chromosomal segments.
We analyzed the cases for extended regions of homozygosity with
simultaneous allele sharing. Only one genome region, which
coincided with the associated interval on CFA 2, fulfilled our
search criteria. Here, all 7 affected dogs were homozygous and
shared identical alleles over 229 SNP markers corresponding to
a ,3.5 Mb interval. We concluded that the causative mutation
should be located in the 3.53 Mb critical interval between the
closest heterozygous markers on either side of the homozygous
segment (CFA2:17,283,880–20,818,258, CanFam 3 assembly;
Figure 1C).
Mutation Identification
A total of 33 genes and loci are annotated in the critical interval
on CFA 2 (CanFam 3.1, Table S1). In order to obtain
a comprehensive overview of all variants in the critical interval
we sequenced the whole genome of one affected Border Collie. We
collected 127 million 26100 bp paired-end reads from a shotgun
fragment library corresponding to roughly 106 coverage of the
genome. We called SNPs and indel variants with respect to the
reference genome of a presumably non-affected Boxer. Across the
entire genome, we detected 2.5 million homozygous variants
(Table 1). Within the critical interval there were 3,173 variants, of
which 17 were predicted to be non-synonymous (Table S2). We
further compared the genotypes of the affected Border Collie with
12 dog genomes of various breeds that had been sequenced in our
laboratory in the course of other ongoing studies. We hypothesized
that the mutant allele at the causative variant should be completely
absent from all other dog breeds outside Border Collies as the
large size of the associated haplotype clearly indicated a relatively
young origin of the mutation. Therefore, we considered it unlikely
that the mutant allele would have been introgressed into any other
breeds outside Border Collies. Among the 17 non-synonymous
variants, there were only 3 variants where the affected Border
Collie carried the homozygous variant genotype and all other 12
sequenced dogs carried the homozygous wildtype genotype
(Table 2).
We genotyped all remaining non-synonymous variants in larger
cohorts of dogs (Table 3). Two variants, MRC1:c.2143C.T and
CUBN:c.8392delC, were perfectly associated with IGS in a cohort
of 200 Border Collies. These variants were absent from more than
300 dogs of other breeds. The MRC1:c.2143C.T variant
represents a nonsense mutation and is predicted to truncate more
than 50% of the mannose receptor, C type 1 (p.R715*). The
CUBN:c.8392delC variant is predicted to result in a frameshift and
early premature termination codon in the open reading frame
encoding cubilin (p.Q2798Rfs*3; Figure 2).
Discussion
Using a purely positional approach, we have identified two
variants that are perfectly associated with IGS in Border Collies.
Both of these variants in the MRC1 and CUBN genes, respectively,
lead to premature stop codons and are predicted to completely
abolish the function of the encoded proteins. The MRC1 gene
encodes the mannose receptor, C type 1, which is expressed on
macrophages and endothelial cells of the liver. MRC1 has
a presumed role in the immune system by acting as an essential
regulator of inflammation-related serum glycoproteins [16]. Mrc1
deficient mice have no obvious phenotype other than elevated
serum lysosomal enzymes related to slower clearance of serum
glycoproteins, including the acid hydrolases [16,17].
The CUBN gene encoding cubilin on the other hand has a well
established role in cobalamin uptake. Mutations in this gene have
been shown to cause IGS, also termed megaloblastic anemia 1 in
humans (MGA1, OMIM #261100) [4]. In contrast to MRC1,
CUBN is thus an excellent functional candidate gene for the
hereditary cobalamin malabsorption disorder observed in Border
Collies. We therefore conclude that the CUBN:c.8392delC variant
is the most likely causative defect for the phenotype, which we
propose to call IGS in analogy to the human disease. According to
our knowledge, these are the first dogs with a characterized
molecular defect in the CUBN gene. Together with AMN mutant
Australian Shepherd Dogs and Giant Schnauzers [7] the CUBN
mutant Border Collies now complete the repertoire of molecular
characterized dog models for IGS in humans.
CUBN Mutation in Border Collies
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The carrier frequency of dogs being heterozygous for the
CUBN:c.8392delC variant in a cohort of nearly 200 randomly
selected Border Collies is relatively low at 6.2%.
This study highlights the power of complete genome re-
sequencing. Using this approach we were able to quickly identify
the most likely causative variant for IGS in Border Collies. This
variant could also have been obtained by a conventional candidate
gene approach. In the case of IGS however, the two known
candidate genes would have comprised a total of 79 exons, and the
individual design of PCR primers and traditional workflow of
PCR-amplifying each exon followed by Sanger sequencing would
have required about the same amount of time and money in our
laboratory as the whole genome re-sequencing experiment. In
contrast to data from a conventional and more limited candidate
gene approach, our analysis has also revealed the unexpected
finding of a nonsense mutation in the MRC1 gene. The MRC1
variant is located 849 kb away from the CUBN frameshift variant
on dog chromosome 2. Both variants appear to segregate only in
Border Collies and have thus most likely arisen within the last 200
years. Unfortunately, the MRC1 and CUBN variants were in
perfect linkage disequilibrium in all available dogs of our study, so
that we could not disentangle the functional effects of each variant
separately. Nonetheless, the seven IGS affected Border Collies did
not show any obvious differences in their clinical phenotype with
respect to other dogs with primary cobalamin absorption
disorders. In particular they showed no signs of immunodeficiency
Figure 1. Mapping of IGS in Border Collies. (A) A genome-wide association study using 7 cases and 7 controls indicates a signal on CFA 2. (B)
The detailed view of CFA 2 delineates an associated interval of ,5 Mb. (C) Homozygosity mapping. Each horizontal bar corresponds to the CFA 2
genotypes of the 7 analyzed cases. Homozygous regions with shared alleles are shown in blue. A shared homozygous interval delineates the exact
boundaries of the critical interval from 17,283,880 to 20,818,258 bp (CanFam 3 assembly).
doi:10.1371/journal.pone.0061144.g001
Table 1. Variants detected by whole genome re-sequencing of an affected Border Collie.
Filtering step Number of variants
Variants in the whole genomea 2,519,661
Variants in the critical 3.53 Mb interval on CFA 2 3,173
Variants in the critical interval that were absent from 12 other dog genomes 243
Non-synonymous variants in the whole genomea 68,303
Non-synonymous variants in the critical 3.53 Mb interval on CFA 2 17
Non-synonymous variants in the critical interval that were absent from 12 other dog genomes 3
aThe sequences were compared to the reference genome (CanFam 3) from a Boxer. Only variants that were homozygous in the affected Border Collie are reported.
doi:10.1371/journal.pone.0061144.t001
CUBN Mutation in Border Collies
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or exaggerated inflammatory reactions (data not shown). It
therefore appears that a spontaneous inactivation of the MRC1
gene in dogs does not result in any obvious clinical phenotype,
similar to what has been observed in Mrc1 knock out mice [16].
In conclusion the identification of a candidate causative
mutation for IGS in Border Collies provides the first dog model
for IGS with a molecular characterized CUBN defect. Our
findings will allow the development of a genetic test and
eradication of IGS from the privately owned Border Collie
breeding population.
Materials and Methods
Ethics Statement
All animal experiments were performed according to the local
regulations. The dogs in this study were examined with the
consent of their owners. The study was approved by the
‘‘Cantonal Committee For Animal Experiments’’ (Canton of
Bern; permits 22/07 and 23/10).
Animal Selection
We used 7 Border Collie cases, which could be unambigu-
ously phenotyped based on small growth, poor BCS, undetect-
able serum cobalamin concentrations, methylmalonic aciduria,
homocysteinemia (4/7) and complete clinical response to
exclusive parenteral cobalamin supplementation. These were
all affected dogs that we could obtain for the study and thus
represent a convenience sample. Two of the cases were full-
siblings. The 7 control Border Collies for the GWAS were
judged to be healthy based on unremarkable history and
physical examination, as well as normal normal results of CBC,
serum biochemistry, urinalysis, serum cobalamin, urinary
methylmalonic acid, and plasma homocysteine concentration.
We classified additional dogs as controls based on owner-
reported unremarkable histories. The complete cohort for this
study consisted of 200 Border Collies and 357 dogs of diverse
other breeds (Table S3). We collected EDTA blood samples
from all dogs.
DNA Samples and SNP Genotyping
We isolated genomic DNA samples from EDTA blood with the
Nucleon Bacc2 kit (GE Healthcare). Genotyping was done on
illumina canine_HD chips containing 173,662 SNP markers at the
NCCR Genomics Platform of the University of Geneva.
Genotypes were stored in a BC/Gene database version 3.5 (BC/
Platforms).
Genome-wide Association Study (GWAS) and
Homozygosity Mapping
We used PLINK v1.07 [18] to perform genome-wide
association analyses (GWAS). We removed markers and
individuals with call rates ,90% from the analysis. We also
removed markers with minor allele frequency (MAF) ,5% and
markers strongly deviating from Hardy-Weinberg equilibrium
(p,1025). We performed an allelic association study using the –
assoc command of PLINK. We also used PLINK to search for
extended intervals of homozygosity with shared alleles as
described previously [19].
Statistics
Raw p-values in the GWAS are based on x2 tests of the allele
frequency in cases vs the allele frequency in controls for each
marker. After the filtering procedures described above, we had
112,323 markers left for the final analysis. In order to correct for
the multiple testing situation, we determined an empirical
significance threshold by performing 100,000 permutations of
the dataset with arbitrarily assigned phenotypes.
Gene Analysis
We used the dog CanFam 3 genome assembly derived from
a Boxer as reference genome sequence. All numbering within the
canine CUBN gene corresponds to the accessions
NM_001003148.1 (mRNA) and NP_001003148.1 (protein).
Table 2. Three non-synonymous variants in the critical interval of an affected Border Collie that were absent from 12 other dog
genomes.
Position on CFA 2
(CanFam 3 assembly) Reference allele Variant allele Gene Variant (cDNA) Variant (protein)
19,125,603 G A MRC1 c.2143C.T p.R715*
19,974,334 C – CUBN c.8392delC p.Q2798Rfs*3
19,999,374 G C CUBN c.9215G.C p.S3072T
doi:10.1371/journal.pone.0061144.t002
Figure 2. Sanger sequencing of the CUBN:c.8392delC variant.
Electropherograms of a homozygous wildtype, heterozygous, and
homozygous mutant dog, respectively, are shown. The position of the
deletion is indicated by arrows. The predicted amino acid translation is
shown above the sequence. Altered codons in the affected dog are
shown in red. The deletion results in an early premature stop codon
(p.Q2798Rfs*3).
doi:10.1371/journal.pone.0061144.g002
CUBN Mutation in Border Collies
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Whole Genome Sequencing of an Affected Border Collie
We prepared a fragment library with 300 bp insert size and
collected one lane of illumina HiSeq2000 paired-end reads
(26100 bp). We obtained a total of 125,457,731 paired-end reads
or roughly 106 coverage. We mapped the reads to the dog
reference genome with the Burrows-Wheeler Aligner (BWA)
version 0.5.9-r16 [20] with default settings and obtained
243,130,060 uniquely mapping reads. After sorting the mapped
reads by the coordinates of the sequence with Picard tools, we
labeled the PCR duplicates also with Picard tools (http://
sourceforge.net/projects/picard/). We used the Genome Analysis
Tool Kit (GATK version 0591, [21]) to perform local realignment
and to produce a cleaned BAM file. Variants calls were then made
with the unified genotyper module of GATK. Variant data for
each sample were obtained in variant call format (version 4.0) as
raw calls for all samples and sites flagged using the variant
filtration module of GATK. Variant calls that failed to pass the
following filters were labeled accordingly in the call set: (i) Hard to
Validate MQ0$4 & ((MQ0/(1.0 * DP)) .0.1); (ii) strand bias (low
Quality scores) QUAL ,30.0 || (Quality by depth) QD ,5.0 ||
(homopolymer runs ) HRun .5 || (strand bias) SB .0.00; (iii)
SNP cluster window size 10. The snpEFF software [22] together
with the CanFam 3.1 annotation was used to predict the
functional effects of detected variants.
Sanger Sequencing
We used Sanger sequencing to confirm the illumina sequencing
results and to perform targeted genotyping for selected variants.
For these experiments we amplified PCR products using
AmpliTaqGold360Mastermix (Applied Biosystems). PCR prod-
ucts were directly sequenced on an ABI 3730 capillary sequencer
(Applied Biosystems) after treatment with exonuclease I and
shrimp alkaline phosphatase. We analyzed the sequence data with
Sequencher 4.9 (GeneCodes).
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